Intranasal Naloxone

Access to naloxone is a priority for reducing opioid deaths. Intranasal Naloxone aimed at assisting in acute emergency situations like opioid overdose. 

nasusphrma taffix

Medical need

In 2017 ~72000 overdose death in the USA~42000 from opioids.

Regulatory requirements

Bioequivalence study –”equal or better”

Nasus pharma presented clinical results at Fourth Annual
ASPN Conference, July 14-17, Miami Beach

nasusphrma taffix

Nasus Pharma announces publication of its pivotal study comparing its FMXIN001 powder nasal Naloxone to Narcan® – READ MORE

nasusphrma taffix
nasusphrma taffix
nasusphrma taffix

Pilot Study

nasusphrma taffix
nasusphrma taffix

The peak systemic exposure was approximately

1.6 fold higher

The partial AUC0-4 minutes was approximately​

7 fold higher

The partial AUC0-10 minutes was approximate

4 fold higher 

The partial AUC10-30 minutes was approximate

1.6 fold higher

The total systemic exposure was approximate

1.26 fold higher

The median Tmax occurred approximately

5 minutes earlier

Contact us for more information

To request more information , please submit your contact details below: